Stockscreener 앱 받기
4.37
9.34%
-0.45
시간 외 거래:
4.36
-0.010
-0.23%
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
3 Key Healthcare Conferences Where CAMP4 Therapeutics Will Share Its regRNA Innovation - StockTitan
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CAMP4 Therapeutics CEO to Present Corporate Update at J.P. Morgan Healthcare Conference - StockTitan
Strategic Investment Boosts Exploration Plans in Ontario's Gold Camp - Streetwise Reports
Camp4 Therapeutics sees MAD safety and key biomarker data in 2H25 - TipRanks
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones - The Manila Times
CAMP4 Therapeutics Advances Urea Cycle Disorder Drug After $82M IPO, Secures BioMarin Partnership - StockTitan
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - citybiz
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
CAMP4 Therapeutics to Present at Piper Sandler Healthcare Conference in NYC | CAMP Stock News - StockTitan
CAMP4 Reports Third Quarter 2024 Financial Results - The Manila Times
CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz
Camp4 Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CAMP4 Therapeutics Secures $370M BioMarin Deal, Raises $82M in IPO Milestone | CAMP Stock News - StockTitan
CalAmp Files Bankruptcy to Complete Debt Restructuring - MSN
Camp4 gains after earning bullish views on Street - MSN
Biopharma IPOs raise nearly $1B in October from 5 public debuts - BioWorld Online
William Blair Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
October IPOs in Biotech, Cleantech, Transportation, Retail and Homebuilder Sectors - Investorideas.com newswire
Camp4 Therapeutics initiated with an Overweight at Piper Sandler - MSN
JP Morgan Initiates Coverage of Camp4 Therapeutics (CAMP) with Overweight Recommendation - MSN
JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech - Investing.com Australia
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
Camp4 stock gains after earning bullish views (CAMP:NASDAQ) - Seeking Alpha
William Blair upbeat on CAMP4 shares with Outperform rating - Investing.com
William Blair upbeat on CAMP4 shares with Outperform rating By Investing.com - Investing.com Canada
Leerink sets stock target for CAMP4, cites broad UCD treatment potential - Investing.com India
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology - Investing.com
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Internet of Things (IoT) in Construction Market Worth Over $61.7 Billion by 2030Industry Analysis and Forecast with Profiles of 37 Major Companies Including Autodesk, Calamp Corp, Caterpillar, Dronedeploy - GlobeNewswire
(PDF) The Effectiveness of Incarceration‐Based Drug Treatment on Criminal Behavior: A Systematic Review - ResearchGate
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Camp4 Therapeutics sees $8.4 million stock purchase by Northpond Ventures - Investing.com India
Camp4 Therapeutics sees $7.99m stock purchase by investors By Investing.com - Investing.com India
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com India
CAMP4 Rings the Opening Bell - Nasdaq
1.03%
자본화:
|
볼륨(24시간):